AAPL344.82-2.29 (-0.66%) ▼|ABBV285.63-0.76 (-0.27%) ▼|ABT103.47+0.37 (+0.36%) ▲|ACN246.40+11.24 (+4.78%) ▲|ADBE248.32-0.04 (-0.02%) ▼|AMAT407.12+11.19 (+2.83%) ▲|AMD561.27+1.01 (+0.18%) ▲|AMGN452.29+4.34 (+0.97%) ▲|AMT179.01-4.83 (-2.62%) ▼|AMZN253.58+0.48 (+0.19%) ▲|AVGO345.00+2.67 (+0.78%) ▲|AXP316.40+3.49 (+1.11%) ▲|BA165.92-2.26 (-1.34%) ▼|BAC50.84+0.16 (+0.31%) ▲|BKNG148.55-1.59 (-1.06%) ▼|BLK1,146.88+10.83 (+0.95%) ▲|BMY61.01-0.55 (-0.89%) ▼|BNY148.20+0.62 (+0.42%) ▲|BRK-B543.01+0.02 (+0.00%) ▲|C123.50+0.81 (+0.66%) ▲|CAT709.64-3.67 (-0.51%) ▼|CL91.98-0.19 (-0.21%) ▼|CMCSA21.66-0.19 (-0.85%) ▼|COF204.31+0.87 (+0.43%) ▲|COP148.95+0.99 (+0.67%) ▲|COST982.90-9.23 (-0.93%) ▼|CRM243.26+2.37 (+0.98%) ▲|CSCO110.51-0.88 (-0.79%) ▼|CVS90.74-0.39 (-0.43%) ▼|CVX229.48+1.25 (+0.55%) ▲|DE642.59+3.01 (+0.47%) ▲|DHR237.13+5.13 (+2.21%) ▲|DIS109.20-1.03 (-0.93%) ▼|DUK124.62-0.19 (-0.15%) ▼|EMR167.91+1.64 (+0.99%) ▲|FDX302.00-5.10 (-1.66%) ▼|GD353.63-1.27 (-0.36%) ▼|GE297.86+0.20 (+0.07%) ▲|GEV864.11-30.97 (-3.46%) ▼|GILD160.07+0.99 (+0.62%) ▲|GM80.03-0.51 (-0.63%) ▼|GOOG320.98+4.15 (+1.31%) ▲|GOOGL324.62+4.04 (+1.26%) ▲|GS919.41+7.64 (+0.84%) ▲|HD320.83+2.33 (+0.73%) ▲|HON218.80-0.01 (0.00%) ▼|IBM252.04+1.79 (+0.72%) ▲|INTC93.26-0.48 (-0.51%) ▼|INTU333.00+4.55 (+1.39%) ▲|ISRG447.90+2.02 (+0.45%) ▲|JNJ269.83+1.10 (+0.41%) ▲|JPM337.26+1.47 (+0.44%) ▲|KO91.66+0.48 (+0.53%) ▲|LIN507.09-1.56 (-0.31%) ▼|LLY1,292.56+10.65 (+0.83%) ▲|LMT620.84-2.15 (-0.35%) ▼|LOW199.79+1.61 (+0.81%) ▲|LRCX247.76+6.91 (+2.87%) ▲|MA614.07+4.22 (+0.69%) ▲|MCD251.93+2.46 (+0.99%) ▲|MDLZ62.12-0.24 (-0.38%) ▼|MDT95.56+1.61 (+1.71%) ▲|META616.33-3.87 (-0.62%) ▼|MMM172.33+0.75 (+0.44%) ▲|MO73.31-0.18 (-0.24%) ▼|MRK141.58-0.25 (-0.17%) ▼|MS187.89+0.98 (+0.52%) ▲|MSFT529.84-1.49 (-0.28%) ▼|MU968.67+39.91 (+4.30%) ▲|NEE81.77-0.65 (-0.79%) ▼|NFLX61.87-0.65 (-1.04%) ▼|NKE37.53-0.04 (-0.09%) ▼|NOW153.52-1.26 (-0.81%) ▼|NVDA217.52-0.43 (-0.20%) ▼|ORCL130.78+0.25 (+0.19%) ▲|PEP132.45-1.05 (-0.79%) ▼|PFE29.73-0.08 (-0.25%) ▼|PG159.07-0.16 (-0.10%) ▼|PLTR195.32-3.42 (-1.72%) ▼|PM202.57-0.05 (-0.02%) ▼|QCOM183.07-1.10 (-0.60%) ▼|RTX195.30+0.70 (+0.36%) ▲|SBUX103.24+0.20 (+0.19%) ▲|SCHW88.58-0.72 (-0.81%) ▼|SO92.58-0.08 (-0.08%) ▼|SPG211.83-0.46 (-0.21%) ▼|T20.78-0.16 (-0.76%) ▼|TMO710.53+17.51 (+2.53%) ▲|TMUS145.19-1.64 (-1.12%) ▼|TSLA399.09-8.37 (-2.05%) ▼|TXN308.84-0.08 (-0.02%) ▼|UBER64.94-0.84 (-1.28%) ▼|UNH414.28+3.89 (+0.95%) ▲|UNP299.13-0.75 (-0.25%) ▼|UPS104.92-1.17 (-1.10%) ▼|USB59.61-0.13 (-0.22%) ▼|V401.52-0.34 (-0.08%) ▼|VZ43.52-0.42 (-0.94%) ▼|WFC83.44+0.78 (+0.94%) ▲|WMT118.83-0.49 (-0.41%) ▼|XOM181.67+1.76 (+0.98%) ▲|AAPL344.82-2.29 (-0.66%) ▼|ABBV285.63-0.76 (-0.27%) ▼|ABT103.47+0.37 (+0.36%) ▲|ACN246.40+11.24 (+4.78%) ▲|ADBE248.32-0.04 (-0.02%) ▼|AMAT407.12+11.19 (+2.83%) ▲|AMD561.27+1.01 (+0.18%) ▲|AMGN452.29+4.34 (+0.97%) ▲|AMT179.01-4.83 (-2.62%) ▼|AMZN253.58+0.48 (+0.19%) ▲|AVGO345.00+2.67 (+0.78%) ▲|AXP316.40+3.49 (+1.11%) ▲|BA165.92-2.26 (-1.34%) ▼|BAC50.84+0.16 (+0.31%) ▲|BKNG148.55-1.59 (-1.06%) ▼|BLK1,146.88+10.83 (+0.95%) ▲|BMY61.01-0.55 (-0.89%) ▼|BNY148.20+0.62 (+0.42%) ▲|BRK-B543.01+0.02 (+0.00%) ▲|C123.50+0.81 (+0.66%) ▲|CAT709.64-3.67 (-0.51%) ▼|CL91.98-0.19 (-0.21%) ▼|CMCSA21.66-0.19 (-0.85%) ▼|COF204.31+0.87 (+0.43%) ▲|COP148.95+0.99 (+0.67%) ▲|COST982.90-9.23 (-0.93%) ▼|CRM243.26+2.37 (+0.98%) ▲|CSCO110.51-0.88 (-0.79%) ▼|CVS90.74-0.39 (-0.43%) ▼|CVX229.48+1.25 (+0.55%) ▲|DE642.59+3.01 (+0.47%) ▲|DHR237.13+5.13 (+2.21%) ▲|DIS109.20-1.03 (-0.93%) ▼|DUK124.62-0.19 (-0.15%) ▼|EMR167.91+1.64 (+0.99%) ▲|FDX302.00-5.10 (-1.66%) ▼|GD353.63-1.27 (-0.36%) ▼|GE297.86+0.20 (+0.07%) ▲|GEV864.11-30.97 (-3.46%) ▼|GILD160.07+0.99 (+0.62%) ▲|GM80.03-0.51 (-0.63%) ▼|GOOG320.98+4.15 (+1.31%) ▲|GOOGL324.62+4.04 (+1.26%) ▲|GS919.41+7.64 (+0.84%) ▲|HD320.83+2.33 (+0.73%) ▲|HON218.80-0.01 (0.00%) ▼|IBM252.04+1.79 (+0.72%) ▲|INTC93.26-0.48 (-0.51%) ▼|INTU333.00+4.55 (+1.39%) ▲|ISRG447.90+2.02 (+0.45%) ▲|JNJ269.83+1.10 (+0.41%) ▲|JPM337.26+1.47 (+0.44%) ▲|KO91.66+0.48 (+0.53%) ▲|LIN507.09-1.56 (-0.31%) ▼|LLY1,292.56+10.65 (+0.83%) ▲|LMT620.84-2.15 (-0.35%) ▼|LOW199.79+1.61 (+0.81%) ▲|LRCX247.76+6.91 (+2.87%) ▲|MA614.07+4.22 (+0.69%) ▲|MCD251.93+2.46 (+0.99%) ▲|MDLZ62.12-0.24 (-0.38%) ▼|MDT95.56+1.61 (+1.71%) ▲|META616.33-3.87 (-0.62%) ▼|MMM172.33+0.75 (+0.44%) ▲|MO73.31-0.18 (-0.24%) ▼|MRK141.58-0.25 (-0.17%) ▼|MS187.89+0.98 (+0.52%) ▲|MSFT529.84-1.49 (-0.28%) ▼|MU968.67+39.91 (+4.30%) ▲|NEE81.77-0.65 (-0.79%) ▼|NFLX61.87-0.65 (-1.04%) ▼|NKE37.53-0.04 (-0.09%) ▼|NOW153.52-1.26 (-0.81%) ▼|NVDA217.52-0.43 (-0.20%) ▼|ORCL130.78+0.25 (+0.19%) ▲|PEP132.45-1.05 (-0.79%) ▼|PFE29.73-0.08 (-0.25%) ▼|PG159.07-0.16 (-0.10%) ▼|PLTR195.32-3.42 (-1.72%) ▼|PM202.57-0.05 (-0.02%) ▼|QCOM183.07-1.10 (-0.60%) ▼|RTX195.30+0.70 (+0.36%) ▲|SBUX103.24+0.20 (+0.19%) ▲|SCHW88.58-0.72 (-0.81%) ▼|SO92.58-0.08 (-0.08%) ▼|SPG211.83-0.46 (-0.21%) ▼|T20.78-0.16 (-0.76%) ▼|TMO710.53+17.51 (+2.53%) ▲|TMUS145.19-1.64 (-1.12%) ▼|TSLA399.09-8.37 (-2.05%) ▼|TXN308.84-0.08 (-0.02%) ▼|UBER64.94-0.84 (-1.28%) ▼|UNH414.28+3.89 (+0.95%) ▲|UNP299.13-0.75 (-0.25%) ▼|UPS104.92-1.17 (-1.10%) ▼|USB59.61-0.13 (-0.22%) ▼|V401.52-0.34 (-0.08%) ▼|VZ43.52-0.42 (-0.94%) ▼|WFC83.44+0.78 (+0.94%) ▲|WMT118.83-0.49 (-0.41%) ▼|XOM181.67+1.76 (+0.98%) ▲|
13.7 C
New York
Wednesday, October 28, 2026

Tag: systemic therapies

newsFORsourcecompanycontentinformation1releasesmarket

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.

Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)

London – 9 July 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PS-002, enabling the initiation of a Phase I/II clinical trial in patients with primary IgA nephropathy (IgAN).

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

– If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors –

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSystemic therapies

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers